Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) Delivers a Reduction and Delay in Worsening of Pain Symptoms for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant
An ongoing phase 3 trial of transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) demonstrated significant improvement in progression-free survival with daratumumab, lenalidomide, and dexamethasone (D-Rd) vs Rd alone (MAIA clinical trial; Facon T, et al. N Engl J Med. 2019;380:2104-15). Bone pain is a common presenting symptom in patients with multiple myeloma (MM), and pain has a significant impact on a person's everyday activity and health-related quality of life (HRQoL).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Katharine Gries, Thierry Facon, Torben Plesner, Saad Usmani, Shaji Kumar, Robert Z. Orlowski, Nizar J. Bahlis, Hareth Nahi, Peter Mollee, Karthik Ramasamy, Murielle ROUSSEL, Michel Delforge, Lionel KARLIN, Bertrand Arnulf, Ajai Chari, Cyrille HULIN, Katja Source Type: research
More News: Clinical Trials | Dexamethasone | Hematology | Leukemia | Lymphoma | Myeloma | Pain | Revlimid | Transplants